News Releases
“As more and more allergists consider incorporating OIT into their clinical practice as a potential treatment approach for people with food allergies, it’s important that the implementation can be seamless from a logistical perspective and enable allergists to continue to deliver personalized care, similar to what they’re familiar with when performing environmental allergy shots which are already part of their established practice,” said
In a double-blinded, self-administered online survey of 80 allergists and immunologists who prescribe both OIT and SCIT, patterns of effective clinical practice logistics showed that the ratio of clinical staff to providers was generally comparable for administering both approaches, with the majority of respondents reporting ratios of either 2:1 or 3:1 of clinical staff to providers. While the staffing needs for SCIT were somewhat greater than those for OIT, they varied based on the volume of patients treated.
Additional study findings suggest that the number of needed exam rooms also varied based on patient volume. The majority of OIT patient needs were met with either one room set aside or by using general allergy care exam rooms. Nearly 60% of physicians indicated that the duration of the patient consent process differed for food OIT and environmental SCIT, with about 90% of those reporting that the consent process for SCIT is shorter than for food OIT. However, the survey also highlights that efficient modules for patient education may provide for more streamlined informed consent processes.
OIT involves retraining the immune system by introducing small doses of an allergen into an individual’s diet and gradually building up to larger amounts over time. Under the close supervision of a trained allergist, patients ingest small amounts of the allergen, which is then steadily increased over time. The goal is to gradually desensitize the patient to the allergen, thus reducing the likelihood of a severe allergic reaction in the event the patient accidently ingests the allergen. Once they reach the therapeutic dose of the OIT treatment, patients will continue to take a daily dose to maintain desensitization. Despite the promise of OIT in treating patients with food allergies, there are currently no guidelines on how to implement OIT into clinical practice to encourage widespread adoption.
About Aimmune
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: the reaction to study results regarding implementation of OIT in clinical practice, the OIT process for desensitization, Aimmune’s expectations regarding the potential benefits of AR101; and Aimmune’s expectations regarding potential applications of the CODIT™ approach to treating potentially life-threatening food allergies. Risks and uncertainties that contribute to the uncertain nature of the forward-looking statements include: the expectation that Aimmune will need additional funds to finance its operations; the unpredictability of the regulatory process; the possibility that Aimmune’s or any of its collaborative partners’ clinical trials will not be successful; Aimmune’s dependence on the success of AR101; Aimmune’s reliance on third parties for the manufacture of Aimmune’s product candidates; possible regulatory developments in
This press release concerns AR101 and AR201, product candidates that are under clinical investigation. Neither AR101 nor AR201 has been approved for marketing by the
View source version on businesswire.com: https://www.businesswire.com/news/home/20191108005165/en/
Source:
Investors:
DeDe Sheel
(917) 834-1494
dsheel@aimmune.com
Media:
Lauren Barbiero
(646) 564-2156
lbarbiero@w2ogroup.com